Abstract
Background: Brodalumab is a fully human interleukin 17 receptor A antagonist efficacious in treating moderate-to-severe plaque psoriasis. Herein, we evaluate the efficacy of brodalumab by self-identified gender in patients with nail or scalp psoriasis in a post hoc analysis of phase 3 studies (AMAGINE-1/-2/-3).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
